Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€316.85

€316.85

0.380%
1.2
0.380%
€327.47
 
30.06.26 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Amgen Inc. Stock

Amgen Inc. gained 0.380% compared to yesterday.
The stock is one of the favorites of our community with 34 Buy predictions and 3 Sell predictions.
With a target price of 327 € there is a slightly positive potential of 3.2% for Amgen Inc. compared to the current price of 316.85 €.
So far the community has only identified positive things for Amgen Inc. stock. The most positive votes were given for criterium "Balance Sheet Risk".

Pros and Cons of Amgen Inc. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Amgen Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Amgen Inc. 0.380% 3.953% 9.751% 33.692% 13.100% 55.777% 54.110%
Regeneron Pharmaceuticals Inc. -1.050% 0.442% 3.783% 22.536% -17.687% -17.162% 15.865%
IQVIA Holdings Inc. 0.470% 12.359% 8.224% 26.430% -12.429% -17.913% -17.270%
Incyte Corp. -0.450% 8.128% 19.653% 71.636% 17.834% 73.983% 39.893%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-14

Die Geldeinnahmen von Amgen (US-Symbol AMGN) deuten auf eine starke Leistung hin, die sich in entscheidenden Finanzmetriken wie Umsatz, Betriebskapital und Rentabilität widerspiegelt. Die Bilanzen des Unternehmens über die Jahre zeigen eine beständige Vermögensbasis und anhaltende Rentabilität. Die Analyse der Cashflow-Berichte zeigt, dass das Unternehmen robuste Betriebscashflows generiert, was auf solide betriebliche Leistung und Liquiditätsmanagement hindeutet.

Gehen wir tiefer in die einzelnen Vorteile und Nachteile der Finanzen von Amgen ein.

Die umfangreichen Vermögenswerte von Amgen, wie in den Jahresbilanzen gezeigt, beinhalten sowohl kurzfristige Vermögenswerte, die eine starke Liquidität signalisieren, als auch längerfristige Vermögenswerte, die eine solide Investition in den Forschungs- und Entwicklungsbereich verdeutlichen.

Comments

Amgen (AMGN) had its "positive" rating reaffirmed by Royal Bank Of Canada.
Ratings data for AMGN provided by MarketBeat
Show more

Amgen (AMGN) was upgraded by Wall Street Zen from "hold" to "buy".
Ratings data for AMGN provided by MarketBeat
Show more

Amgen (AMGN) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for AMGN provided by MarketBeat
Show more

News

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/7089e9c275d4f6f9668a8e5e172ac46be0ed0aaa-1200x800.png?w=800&q=75&fit=max&auto=format
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Does the established stability of a pharmaceutical giant outweigh the explosive growth potential of a specialized cancer fighter? Investors choosing between Amgen (NASDAQ:AMGN) and Iovance

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/2d10dfb318519977a677bcb00f3da6d28e64e4b0-1200x800.png?w=800&q=75&fit=max&auto=format
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Deciding between a pharmaceutical giant and a niche medical innovator depends on your risk tolerance. Amgen (NASDAQ:AMGN) and NovoCure (NASDAQ:NVCR) offer vastly different paths to potential growth

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Key Points